Bladder Cancer Detection Test: URODIAG®
Urodiag® is an innovative, non-invasive test for monitoring bladder cancer that is analyzed using a urine sample: easy, fast, no prior preparation required, and with high accuracy (99%).
URODIAG® analyzes the presence of genetic and epigenetic markers in cells found in urine. The combination of detecting mutations in the FGFR3 gene and methylation alterations in the HS3ST2, SEPTIN9, and SLIT2 genes enhances and ensures more precise detection.
Urinary biomarkers provide key molecular information to optimize surveillance and personalize treatment for patients with NMIBC.
Non-muscle invasive bladder cancer (NMIBC) is a type of cancer found in the inner layer of the bladder that does not invade the muscle wall. 80% of diagnosed bladder cancer cases are NMIBC.
NMIBC has a high recurrence rate after treatment (>70%), and 10-15% of patients experience progression to muscle-invasive bladder cancer (MIBC), highlighting the clinical importance of identifying these patients.
Continuous monitoring of NMIBC is essential to anticipate disease progression and determine the most appropriate treatment.
Who is this test useful for?
URODIAG® is a non-invasive urine sample test for monitoring patients diagnosed with low, intermediate, and high-risk non-muscle invasive bladder cancer (NMIBC).
- Sample type: urine sample
- Turnaround time: 15 business days (Monday to Friday)
Benefits
- It is a non-invasive procedure.
- No hospitalization or anesthesia required.
- Reduces the number of cystoscopies.
- Provides diagnostic accuracy similar to cystoscopy.
- A more comfortable test for the patient.
Risk Factors
- Smoking
- Exposure to toxic substances
- Advanced age (>50 years)
- Family history
Symptoms
- Hematuria: Blood in urine
- Frequent urination
- Urinary discomfort
What does it analyze?
From a urine sample, the laboratory extracts DNA and performs a real-time quantitative PCR to detect specific mutations in the FGFR3 gene and quantify DNA methylation in the HS3ST2, SEPTIN9, and SLIT2 genes. These genetic markers indicate the presence of non-muscle invasive bladder cancer (NMIBC).
A positive result indicates the presence of genetic alterations associated with bladder cancer, whereas a negative result rules out the presence of aggressive bladder tumors with more than 99% accuracy.
The laboratory provides a detailed report of the detected genetic alterations and an interpretation of the results as positive or negative.
This report is used by physicians to make treatment decisions, personalize treatment plans, and adjust the frequency of cystoscopies and other monitoring and surveillance tests for NMIBC.
